Therapy with Direct-Acting Antiviral Agents for Hepatitis C-Related Liver Cirrhosis
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Therapy with Direct-Acting Antiviral Agents for Hepatitis C-Related Liver Cirrhosis
Authors
Keywords
-
Journal
Gut and Liver
Volume 11, Issue 3, Pages 335-348
Publisher
The Editorial Office of Gut and Liver
Online
2016-11-14
DOI
10.5009/gnl15458
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Grazoprevir–Elbasvir Combination Therapy for Treatment-Naive Cirrhotic and Noncirrhotic Patients With Chronic Hepatitis C Virus Genotype 1, 4, or 6 Infection
- (2015) Stefan Zeuzem et al. ANNALS OF INTERNAL MEDICINE
- Sofosbuvir and Ribavirin Prevent Recurrence of HCV Infection After Liver Transplantation: An Open-Label Study
- (2015) Michael P. Curry et al. GASTROENTEROLOGY
- Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients With Advanced Liver Disease
- (2015) Michael Charlton et al. GASTROENTEROLOGY
- Daclatasvir in Combination With Asunaprevir and Beclabuvir for Hepatitis C Virus Genotype 1 Infection With Compensated Cirrhosis
- (2015) Andrew J. Muir et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- O008 : Efficacy and safety of grazoprevir and elbasvir in hepatitis C genotype 1-infected patients with child–pugh class B cirrhosis (C-salt part A)
- (2015) I.M. Jacobson et al. JOURNAL OF HEPATOLOGY
- G02 : Ledipasvir/sofosbuvir with ribavirin is safe and efficacious in decompensated and post liver transplantation patients with HCV infection: Preliminary results of the prospective solar 2 trial
- (2015) M. Manns et al. JOURNAL OF HEPATOLOGY
- Sofosbuvir plus ribavirin for the treatment of chronic genotype 4 hepatitis C virus infection in patients of Egyptian ancestry
- (2015) Peter J. Ruane et al. JOURNAL OF HEPATOLOGY
- Grazoprevir and elbasvir plus ribavirin for chronic HCV genotype-1 infection after failure of combination therapy containing a direct-acting antiviral agent
- (2015) Xavier Forns et al. JOURNAL OF HEPATOLOGY
- Ledipasvir-sofosbuvir with or without ribavirin to treat patients with HCV genotype 1 infection and cirrhosis non-responsive to previous protease-inhibitor therapy: a randomised, double-blind, phase 2 trial (SIRIUS)
- (2015) Marc Bourlière et al. LANCET INFECTIOUS DISEASES
- Ledipasvir and sofosbuvir fixed-dose combination with and without ribavirin for 12 weeks in treatment-naive and previously treated Japanese patients with genotype 1 hepatitis C: an open-label, randomised, phase 3 trial
- (2015) Masashi Mizokami et al. LANCET INFECTIOUS DISEASES
- Simeprevir versus telaprevir with peginterferon and ribavirin in previous null or partial responders with chronic hepatitis C virus genotype 1 infection (ATTAIN): a randomised, double-blind, non-inferiority phase 3 trial
- (2015) K Rajender Reddy et al. LANCET INFECTIOUS DISEASES
- Preclinical Characterization of BMS-791325, an Allosteric Inhibitor of Hepatitis C Virus NS5B Polymerase
- (2014) Julie A. Lemm et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- In VitroandIn VivoAntiviral Activity and Resistance Profile of Ombitasvir, an Inhibitor of Hepatitis C Virus NS5A
- (2014) Preethi Krishnan et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- In VitroandIn VivoAntiviral Activity and Resistance Profile of the Hepatitis C Virus NS3/4A Protease Inhibitor ABT-450
- (2014) Tami Pilot-Matias et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- In VitroActivity and Resistance Profile of Dasabuvir, a Nonnucleoside Hepatitis C Virus Polymerase Inhibitor
- (2014) Warren Kati et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- New antiviral agents for the treatment of hepatitis C: ABT-450
- (2014) Andres F Carrion et al. EXPERT OPINION ON PHARMACOTHERAPY
- Simeprevir With Peginterferon and Ribavirin Leads to High Rates of SVR in Patients With HCV Genotype 1 Who Relapsed After Previous Therapy: A Phase 3 Trial
- (2014) Xavier Forns et al. GASTROENTEROLOGY
- Effectiveness of Telaprevir or Boceprevir in Treatment-Experienced Patients With HCV Genotype 1 Infection and Cirrhosis
- (2014) Christophe Hézode et al. GASTROENTEROLOGY
- Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection
- (2014) Hiromitsu Kumada et al. HEPATOLOGY
- Global distribution and prevalence of hepatitis C virus genotypes
- (2014) Jane P. Messina et al. HEPATOLOGY
- All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study
- (2014) Michael Manns et al. LANCET
- Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial
- (2014) Ira M Jacobson et al. LANCET
- Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial
- (2014) Michael Manns et al. LANCET
- Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study
- (2014) Eric Lawitz et al. LANCET
- Ledipasvir and Sofosbuvir for Untreated HCV Genotype 1 Infection
- (2014) Nezam Afdhal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ledipasvir and Sofosbuvir for Previously Treated HCV Genotype 1 Infection
- (2014) Nezam Afdhal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Sofosbuvir and Ribavirin in HCV Genotypes 2 and 3
- (2014) Stefan Zeuzem et al. NEW ENGLAND JOURNAL OF MEDICINE
- ABT-450/r–Ombitasvir and Dasabuvir with Ribavirin for Hepatitis C with Cirrhosis
- (2014) Fred Poordad et al. NEW ENGLAND JOURNAL OF MEDICINE
- Review article: the epidemiology and therapy of chronic hepatitis C genotypes 4, 5 and 6
- (2013) J. M. Wantuck et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Discovery of MK-8742: An HCV NS5A Inhibitor with Broad Genotype Activity
- (2013) Craig A. Coburn et al. ChemMedChem
- Efficacy of Nucleotide Polymerase Inhibitor Sofosbuvir Plus the NS5A Inhibitor Ledipasvir or the NS5B Non-Nucleoside Inhibitor GS-9669 Against HCV Genotype 1 Infection
- (2013) Edward J. Gane et al. GASTROENTEROLOGY
- Differential Sensitivity of 5′UTR-NS5A Recombinants of Hepatitis C Virus Genotypes 1−6 to Protease and NS5A Inhibitors
- (2013) Yi-Ping Li et al. GASTROENTEROLOGY
- Sofosbuvir and Ribavirin for Hepatitis C Genotype 1 in Patients With Unfavorable Treatment Characteristics
- (2013) Anuoluwapo Osinusi et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) – NCT01514890
- (2013) Christophe Hézode et al. JOURNAL OF HEPATOLOGY
- Safety and efficacy of protease inhibitors to treat hepatitis C after liver transplantation: A multicenter experience
- (2013) Audrey Coilly et al. JOURNAL OF HEPATOLOGY
- Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial
- (2013) Eric Lawitz et al. LANCET
- Sofosbuvir for Hepatitis C Genotype 2 or 3 in Patients without Treatment Options
- (2013) Ira M. Jacobson et al. NEW ENGLAND JOURNAL OF MEDICINE
- Sofosbuvir for Previously Untreated Chronic Hepatitis C Infection
- (2013) Eric Lawitz et al. NEW ENGLAND JOURNAL OF MEDICINE
- Preclinical Profile and Characterization of the Hepatitis C Virus NS3 Protease Inhibitor Asunaprevir (BMS-650032)
- (2012) Fiona McPhee et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- MK-5172, a Selective Inhibitor of Hepatitis C Virus NS3/4a Protease with Broad Activity across Genotypes and Resistant Variants
- (2012) Vincenzo Summa et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- A randomized controlled trial of pretransplant antiviral therapy to prevent recurrence of hepatitis C after liver transplantation
- (2012) Gregory T. Everson et al. HEPATOLOGY
- Global epidemiology of hepatitis C virus infection: New estimates of age-specific antibody to HCV seroprevalence
- (2012) Khayriyyah Mohd Hanafiah et al. HEPATOLOGY
- A phase 1, randomized, placebo-controlled, 3-day, dose-ranging study of GS-5885, an NS5A inhibitor, in patients with genotype 1 hepatitis C
- (2012) Eric J. Lawitz et al. JOURNAL OF HEPATOLOGY
- Preliminary Study of Two Antiviral Agents for Hepatitis C Genotype 1
- (2012) Anna S. Lok et al. NEW ENGLAND JOURNAL OF MEDICINE
- Hepatitis C virus treatment pre- and post-liver transplantation
- (2011) Bruno Roche et al. LIVER INTERNATIONAL
- Boceprevir for Untreated Chronic HCV Genotype 1 Infection
- (2011) Fred Poordad et al. NEW ENGLAND JOURNAL OF MEDICINE
- Boceprevir for Previously Treated Chronic HCV Genotype 1 Infection
- (2011) Bruce R. Bacon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Telaprevir for Retreatment of HCV Infection
- (2011) Stefan Zeuzem et al. NEW ENGLAND JOURNAL OF MEDICINE
- Telaprevir for Previously Untreated Chronic Hepatitis C Virus Infection
- (2011) Ira M. Jacobson et al. NEW ENGLAND JOURNAL OF MEDICINE
- Management of Hepatitis C Virus Infection Recurrence After Liver Transplantation: An Overview
- (2011) F.R. Ponziani et al. TRANSPLANTATION PROCEEDINGS
- PSI-7851, a Pronucleotide of -D-2'-Deoxy-2'-Fluoro-2'-C-Methyluridine Monophosphate, Is a Potent and Pan-Genotype Inhibitor of Hepatitis C Virus Replication
- (2010) A. M. Lam et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect
- (2010) Min Gao et al. NATURE
- The natural history of hepatitis C cirrhosis after liver transplantation
- (2009) Roberto J. Firpi et al. LIVER TRANSPLANTATION
- Diagnosis, management, and treatment of hepatitis C: An update
- (2008) Marc G. Ghany et al. HEPATOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started